Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

globenewswire.com
BYSI The article announces a poster presentation at a scientific meeting. While this indicates ongoing research and development, it does not provide new clinical data or significant business updates that would strongly influence sentiment.

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California.

Presentation Details:

About BeyondSpring

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to restoring tumor sensitivity to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

Investor Contact: IR@beyondspringpharma.com

Media Contact: PR@beyondspringpharma.com